Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Antitumor activity of arsenite in combination with tetrandrine against human breast cancer cell line MDA-MB-231 in vitro and in vivo

Fig. 1

Cytotoxic effect of AsIII and Tetra, alone or in combination, against human breast cancer cell line MDA-MB-231. Cell viability was determined by XTT assay after the treatment with various concentrations of AsIII alone (0.3, 1, 3, 10, 30 and 100 µM) (a), Tetra alone (2, 4, 6, 8, 10 and 12 µg/ml) (b), their combination in constant ratio (5 µM AsIII + 2 µg/ml Tetra, 10 µM AsIII + 4 µg/ml Tetra, 15 µM AsIII + 6 µg/ml Tetra, 20 µM AsIII + 8 µg/ml Tetra, 25 µM AsIII + 10 µg/ml Tetra, and 30 µM AsIII + 12 µg/ml Tetra) (c), or combination treatment with relatively low concentrations (5 µM AsIII + 3.5 µg/ml Tetra, 10 µM AsIII + 4 µg/ml Tetra, 15 µM AsIII + 4.5 µg/ml Tetra) (d) for 48 h. Relative cell viability was calculated as the ratio of the absorbance at 450 nm of each treatment group against those of the corresponding untreated control group. Data are shown as the means and SD from more than three independent experiments. p < 0.05 vs. each alone. As, AsIII; Tetra, tetrandrine; As + Tetra, AsIII + tetrandrine

Back to article page